Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRAZYR all-case post-marketing surveillance in pediatric hereditary angioedema
jRCT2031220292Completed
- Sponsor
- Takeda
- Start
- Aug 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of icatibant in hereditary angioedema (HAE), sponsored by Takeda. Primary endpoint: Number of participants with at least one treatment-emergent adverse event. Started Aug 2022; status: completed.
02
Drugs
icatibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2031220292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220292.